PMFA
MGNX icon

Plante Moran Financial Advisors’s MacroGenics MGNX Stock Holding History

Plante Moran Financial Advisors’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-22
Closed – – 965
2016
Q4 		$0 Hold
22
– – ﹤0.01% 1013
2016
Q3 		$1K Hold
22
– – ﹤0.01% 894
2016
Q2 		$1K Hold
22
– – ﹤0.01% 863
2016
Q1 		$0 Buy
+22
New +$419 ﹤0.01% 969

Other funds holding MGNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BRC
Blue Ridge Capital New York $215M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Plante Moran Financial Advisors's MGNX Position: Q1 2017 in Review

Plante Moran Financial Advisors sold out of MacroGenics (MGNX) in Q1 2017, closing a stake of 22 shares.

Plante Moran Financial Advisors first reported a position in MGNX in Q1 2016 and held it in 4 quarters. The position peaked at $1K in Q3 2016. 111 funds tracked by Wall St. Rank hold MGNX as of Q1 2017.

  • Plante Moran Financial Advisors reported no remaining MacroGenics position as of Q1 2017 after selling out during the quarter.
  • Plante Moran Financial Advisors sold 22 MacroGenics shares in Q1 2017.
  • Plante Moran Financial Advisors first reported a position in MacroGenics in Q1 2016 and held it in 4 quarters.
  • Plante Moran Financial Advisors's MacroGenics position peaked at $1K in Q3 2016.
  • 111 funds tracked by Wall St. Rank held MacroGenics as of Q1 2017.

Based on Plante Moran Financial Advisors's 13F filing for Q1 2017, filed 1 May 2017.